1. Scrip
  2. >>Business
  3. >>Deals

Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal

Most Observers Still Want More Detailed Data From Urothelial Cancer Study

 
• By Alaric DeArment

Seagen/Astellas announced Phase Ib/II trial data for the combination that could lead to an accelerated approval for the antibody-drug conjugate in first-line bladder cancer.

Seagen/Astellas announced topline results from the Phase Ib/II study of Padcev/Keytruda in urothelial cancer • Source: Shutterstock

Topline results from Seagen Inc. /Astellas Pharma, Inc.’s Phase Ib/II EV-103 trial of Padcev (enfortumab vedotin-ejfv) and Merck & Co., Inc.’s Keytruda (pembrolizumab) in first-line unresectable locally advanced or metastatic urothelial cancer may help bolster investor enthusiasm around the alleged efforts by Merck to buy Seagen. The results themselves look incrementally positive, but it is likely more data will need to come out to provide a sense of how the results might affect practice.

Seagen and Astellas said on 26 July that results demonstrated a 64.5% objective response rate (ORR) in the EV-103 trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

More from Business